Abbott Laboratories 8-K

Summary

Abbott plans to separate its global Nutrition business into an independent, publicly traded company through a tax-free distribution of shares to Abbott shareholders, who would own shares in both companies. Completion is expected by the end of 2027, subject to regulatory approvals, an effective Form 10 registration statement and final board approval; Daniel Salvadori is slated to lead the new company as CEO. Abbott says the separation will not affect its 2026 guidance or the 2027 guidance it plans to provide in January.

Key Figures

• The new Nutrition company is expected to have ≈$8.5B in annual sales, about 16,000 employees and 14 manufacturing sites; Abbott expects ≈$42B in sales after the separation.
• Abbott expects the combined dividend paid by Abbott and the new company to equal Abbott’s dividend at the time of separation.
• Abbott expects one-time transaction charges in periods before the separation; the amount will be quantified later.

Guidance

• Abbott said the separation will not affect its 2026 guidance; it plans to provide 2027 guidance in January and said the separation will not affect it. Figures were not restated.